APM
JSPR icon

Avidity Partners Management’s Jasper Therapeutics JSPR Stock Holding History

Avidity Partners Management’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-782,000
Closed -$17.8M – 91
2024
Q2 		$17.8M Buy
782,000
+22,000
+3% +$528K 0.75% 47
2024
Q1 		$22.3M Buy
+760,000
New +$13.5M 0.72% 46

Other funds holding JSPR

VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
QUSVM
Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Avidity Partners Management's JSPR Position: Q3 2024 in Review

Avidity Partners Management sold out of Jasper Therapeutics (JSPR) in Q3 2024, closing a stake of 782,000 shares — an estimated $17.8M sold.

Avidity Partners Management first reported a position in JSPR in Q1 2024 and held it in 2 quarters. The position peaked at $22.3M in Q1 2024. 81 funds tracked by Wall St. Rank hold JSPR as of Q3 2024.

  • Avidity Partners Management reported no remaining Jasper Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Avidity Partners Management sold 782,000 Jasper Therapeutics shares in Q3 2024, an estimated $17.8M.
  • Avidity Partners Management first reported a position in Jasper Therapeutics in Q1 2024 and held it in 2 quarters.
  • Avidity Partners Management's Jasper Therapeutics position peaked at $22.3M in Q1 2024.
  • 81 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q3 2024.

Based on Avidity Partners Management's 13F filing for Q3 2024, filed 14 Nov 2024.